SCHEMBL89869

SCHEMBL89869

COCCCOc1cc(NC2CC2)c(F)cc1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
EHMT2 Q96KQ7 5/20 0.33
DNMT1 P26358 3/20 0.33
KDM4E B2RXH2 2/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
ROCK2 O75116 1/20 0.33
POLB P06746 1/20 0.32
ACACB O00763 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP2C9 P11712 1/20 0.32
MAPK14 Q16539 1/20 0.32
CD38 P28907 1/20 0.32
RET P07949 1/20 0.31
KIF5B P33176 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90276 0.84 CNR2 (0.35) KMT2AROCK2ACACBGAAEGFR
SCHEMBL90611 0.83 REN (0.39) KDM4EKMT2AACACBALDH1A1CYP2C9
SCHEMBL12055548 0.80 IRAK4 (0.36) EHMT2DNMT1KMT2AHTTALDH1A1
SCHEMBL90173 0.77 LMNA (0.39) KDM4EKMT2ALMNAHTTPOLB
SCHEMBL90434 0.76 ROCK2 (0.38) BRD4ATAD2KDM4ELMNAHTT
SCHEMBL90301 0.75 CCNK (0.41) BRD4ATAD2KDM4EALDH1A1EGFR
SCHEMBL89783 0.73 KDM4E (0.34) KDM4EKMT2ALMNAHTTPOLB
SCHEMBL2085628 0.69 MEN1 (0.43) KDM4EKMT2AHTTPOLBALDH1A1
SCHEMBL89281 0.68 ALDH1A1 (0.44) KDM4EKMT2ALMNAHTTPOLB
SCHEMBL22138650 0.68 MRGPRX4 (0.47) KDM4ELMNAALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 BRD4 603/4885ATAD2 2749/4885EHMT2 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.